Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Deferred Taxes (2024 - 2025)

Adma Biologics (ADMA) has disclosed Deferred Taxes for 2 consecutive years, with -$20.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Deferred Taxes fell 124.76% year-over-year to -$20.9 million, compared with a TTM value of -$11.0 million through Dec 2025, down 113.08%, and an annual FY2025 reading of -$11.0 million, down 113.08% over the prior year.
  • Deferred Taxes was -$20.9 million for Q4 2025 at Adma Biologics, down from $4.8 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $84.3 million in Q4 2024 and bottomed at -$20.9 million in Q4 2025.